Cytogenetics News
-
ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
-
Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
-
Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award
Cellworks Group, Inc., a world leader in Genomic Biosimulation Services for Precision Pharma and Personalized Oncology, today announced it has won The Challengers Innovative Business of the Year Award. Dell Technologies, in collaboration with Moneycontrol, CNBC TV-18, Intel, and Ernst and Young, established The Challengers Awards to recognize the agility and innovation displayed by IT innovators. ...
-
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® (“IPS”), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, ...
-
Cellworks Singula TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A study, which demonstrate that the Cellworks Biosimulation Platform and SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) for non-small cell lung cancer (NSCLC) patients and can provide ...
-
Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In ...
-
Cellworks Singula TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-004 study, which demonstrate that the Cellworks SingulaTM Therapy Response Index (TRI) is highly predictive of Overall Survival (OS), Disease-Free Survival (DFS) and Mandard-tumor regression grade (TRG) for gastroesophageal adenocarcinoma ...
-
myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-023 clinical trial, which found that the Cellworks Biosimulation Platform with its Therapy Response Index (TRI) reliably predicts complete response (CR) and overall survival (OS) for individual Acute Myeloid Leukemia (AML) patients beyond ...
-
Metaglut1, A New Diagnostic Test for the Glut1 Deficiency Syndrome
Laboratoire Cerba and METAFORA biosystems are proud to announce the availability of the innovative test METAglut1 in routine biology to help diagnose the GLUT1 deficiency syndrome (GLUT1-DS) Laboratoire Cerba will perform the METAglut1 diagnostics test developed by METAFORA for the early non-invasive diagnosis of a debilitating neurological disease, the GLUT1 deficiency syndrome (also named De ...
-
Agilent Technologies Introduces OneSeq to Streamline Cytogenetic Research
Agilent Technologies Inc. (NYSE: A) today introduced OneSeq, the industry's first all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research. Agilent is showcasing the new product at the annual Advances in Genome Biology ...
-
Agilent Technologies Joins Forces with Baylor College of Medicine to Provide Customized CGH Microarrays for Cancer, Prenatal and Postnatal Research
Agilent Technologies Inc. (NYSE: A) has announced it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor's data-rich expertise in genetics research with Agilent's microarray manufacturing capabilities to enable ...
-
Agilent Technologies introduces next-generation fluorescent in situ hybridization assays for molecular analysis
Agilent Technologies Inc. (NYSE: A) today introduced Agilent SureFISH probes, the next generation of fluorescent in situ hybridization (FISH) assays, delivering a comprehensive menu of the industry's highest resolution probes for a wide range of molecular analysis applications. Agilent SureFISH probes deliver dramatically better performance compared to existing FISH products. SureFISH probes ...
-
Agilent Introduces CGH+SNP cancer microarrays and Cytogenomics software for cancer research
Agilent Technologies Inc., (NYSE: A) today introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer tissue samples in the same experiment. The new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which now includes support for CGH+SNP analysis of ...
-
Agilent Technologies releases new cytogenetics software, providing complete solution for researchers
Agilent Technologies Inc. (NYSE: A) today introduced Agilent CytoGenomics 1.5 software. This analytical tool gives researchers the ability to streamline their analysis by querying the in-house CytoGenomic database and external databases. The software is designed for easy data interpretation and simple report generation. Agilent provides the most accepted microarray platform for cytogenetics, and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you